Cubist Pharmaceuticals About
Cubist: Cubist Pharmaceuticals, Inc. is a biopharmaceutical
company focused on the research, development and commercialization of products
that address unmet medical needs in the acute care environment. Cubist is primarily
focused on the antiinfective market place. Cubicin® (daptomycin for injection),
the company’s flagship drug, was approved on September 12, 2003, by the U.S. Food
and Drug Administration, for sale in the United States. CUBICIN is approved
for the treatment of complicated skin and skin structure infections (cSSSI) caused
by specific Gram-positive bacteria. Cubist is currently evaluating the
safety and efficacy of CUBICIN for the treatment of infective endocarditis
and bacteremia caused by Staphylococcus.
In June 2004, Cubist entered into a license agreement with XTLbio for
the worldwide development and commercialization of the investigational monoclonal
antibody product currently known as HepeX-B(TM). HepeX-B(TM) is in clinical
trials for the prevention of re-infection by the Hepatitis B virus, or HBV, in
liver transplant patients. Product
Development for Cubist More
on Cubist:
Key
Statistics for Cubist
Phase
IV Daptomycin Soft
Tissue Infection (NIH) Phase
IIb HepeX-B
(monoclonal antibody biologic) prevention
of infection/HepatitisB
Basic
Chart for Cubist